Portal de Periódicos da CAPES

Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal

2019; Massachusetts Medical Society; Volume: 381; Issue: 23 Linguagem: Inglês

10.1056/nejmoa1905047

1533-4406

Mila Shakya, Rachel Colin-Jones, Katherine Theiss-Nyland, Merryn Voysey, Dikshya Pant, Nicola Smith, Xinxue Liu, Susan Tonks, Olga Mazur, Yama F Mujadidi, Jenny Clarke, Jennifer Hill, Anup Adhikari, Sabina Dongol, Abhilasha Karkey, Binod Bajracharya, Sarah Kelly, Meeru Gurung, Stephen Baker, Kathleen M. Neuzil, Shrijana Shrestha, Buddha Basnyat, Andrew J. Pollard,

Vibrio bacteria research studies

Salmonella Typhi is a major cause of fever in children in low- and middle-income countries. A typhoid conjugate vaccine (TCV) that was recently prequalified by the World Health Organization was shown to be efficacious in a human challenge model, but data from efficacy trials in areas where typhoid is endemic are lacking.